Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells.

Li, Suxia; Chen, Suxiu; Jiang, Yiyan; Liu, Jiefan; Yang, Xiaolei; Quan, Shichao.

Affiliation

Li S; Department of Tumor Rehabilitation, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Chen S; Department of Tumor Rehabilitation, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Jiang Y; Department of Tumor Rehabilitation, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Liu J; Department of Tumor Rehabilitation, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Yang X; Department of Tumor Rehabilitation, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Quan S; Department of Tumor Rehabilitation, First Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.

Oncol Lett ; 10(4): 2652-2656, 2015 Oct.

Article in En | MEDLINE | ID: mdl-26622906